Eighteen months on from the acquisition of Olympus by Beckman Coulter, Pathology in Practice spoke to marketing manager Leanne Annereau, a senior manager who came from Olympus to the newly expanded company.
Over the past 18 months, Beckman Coulter has emerged as a stronger, more focused and certainly more resilient player in the global in vitro diagnostics (IVD) market. During this period, it has launched more new products than ever before; and 2011 will see a continuing emphasis on innovation and new product launches.
It was always very clear about our reason for acquiring Olympus. The intention has been to take the best from each company and build a stronger and more efficient business “dedicated to improving patient health and reducing the cost of care”.
The decision was driven by respect for each other’s strengths. The skills and product portfolios were largely complementary, which means together, we are much stronger. Through the acquisition, Beckman Coulter has significantly expanded its ability to supply solutions for the high-throughput and low-volume segments of the clinical diagnostics market, with the AU series of automated clinical chemistry analysers renowned for their quality and reliability. By harnessing our combined strengths in clinical chemistry we have created a new, integrated chemistry systems business, with global R&D, manufacturing and commercial operations capability.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.